Controversies in Radioiodine Treatment of Low- and Intermediate-risk Thyroid Cancer

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)


In differentiated thyroid cancer, radioiodine therapy (RIT) is usually carried out after thyroidectomy. Although the potent beneficial effects of radioiodine are undisputed in high-risk patients, much controversy remains surrounding many aspects of RIT in low- and intermediate-risk patients. Other than the indication for postoperative RIT, controversies also include, among others, the intent of RIT and the choice of activity for RIT or the mode of thyroid stimulating hormone stimulation. Furthermore, there is even controversy on the definition of what constitutes low- or intermediate-risk patients. Here the various issues will be discussed and an overview of the different points of view in a number of more prominent national and international guidelines and current literature is presented.

Original languageEnglish
Pages (from-to)68-74
Number of pages7
JournalClinical Oncology
Issue number2
Publication statusPublished - Feb 2021

Bibliographical note

Publisher Copyright:
© 2020 The Royal College of Radiologists


Dive into the research topics of 'Controversies in Radioiodine Treatment of Low- and Intermediate-risk Thyroid Cancer'. Together they form a unique fingerprint.

Cite this